Recent Updates
Recently added Catalysts
EW Positive Sentiment

Edwards Lifesciences Comments on TAVR National Coverage Decision

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Edwards Lifesciences has expressed satisfaction with the recent national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) issued by CMS. The company views this policy update as a crucial advancement in enhancing patient access to TAVR procedures. Additionally, it emphasizes the importance of a collaborative approach through a multidisciplinary Heart Team in managing aortic stenosis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Updated policy improves patient access to TAVR.
  • Reinforces the value of a multidisciplinary Heart Team.
  • Significant step forward for aortic stenosis treatment.

Full Press Release Details

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro

Frequently Asked Questions

What is the TAVR national coverage decision?

The TAVR national coverage decision is a policy update by CMS that affects patient access to transcatheter aortic valve replacement.

How does Edwards Lifesciences view the NCD?

Edwards Lifesciences is pleased with the NCD, seeing it as a significant step to improve patient access to TAVR.

What is the role of a multidisciplinary Heart Team?

The multidisciplinary Heart Team is emphasized as crucial for managing aortic stenosis and ensuring effective treatment.

ShareAdd on Google
Tags: EW Viatris Investor Conferences Healthcare Edwards Lifesciences TAVR aortic stenosis CMS Heart Team
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$4253M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KetotifenPhase 3
Widespread Chronic Pain →